D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours
Status:
Completed
Trial end date:
2017-06-06
Target enrollment:
Participant gender:
Summary
This is a 2 part study for patients with solid tumours. The purpose of Part A is to measure
the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after
eating 3 different breakfasts (high calorie, regular and none). In Part B Patients can take
olaparib capsules daily and study assessments will be recorded for 6 months (minimum).
Treatment can continue for as long as the patient is benefitting. Throughout the study
patients will be monitored for any side effects.